Status:
UNKNOWN
Study Safety and Efficacy of BMMNC for the Patient With Duchenne Muscular Dystrophy
Lead Sponsor:
Chaitanya Hospital, Pune
Conditions:
Muscular Dystrophy
Duchenne Muscular Dystrophy
Eligibility:
All Genders
4-20 years
Phase:
PHASE1
PHASE2
Brief Summary
This Study is single arm, single center trial to check the safety and efficacy of BMMNC (100 million per dose) for the patient with Duchenne Muscular Dystrophy,
Detailed Description
Muscular dystrophies, or MD, are a group of inherited conditions, which means they are passed down through families. They may occur in childhood or adulthood. There are many different types of muscula...
Eligibility Criteria
Inclusion
- Patient with Diagnose of Duchenne Muscular Dystrophy.
- Aged in between 4 to 20 Years.
- Willingness to undergo Bone Marrow derived Autologous cell Therapy.
- Ability to comprehend the explained protocol and thereafter give an informed consent as well as sign the required Informed Consent form(ICF) for the study.
- Ability and willingness to regular visit to hospital for protocol procedures and follow up
Exclusion
- Patient with History of Immunodeficiency HIV+,Hepatitis B ,HBV and TPPA+, Tumor Markers+
- Patients with History of Hypertension and Hypersensitive.
- Patient who is not Diagnose of Duchenne Muscular Dystrophy.
- Alcohol and drug abuse / dependence.
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2016
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01834040
Start Date
September 1 2014
End Date
October 1 2016
Last Update
September 17 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chaitanya Hospital
Pune, Maharashtra, India, 411009